Table 1. Interacting Residues Involved in Interactions of CYP’s Enzymes and Potential Inhibitorsa.
| enzyme | inhibitor | H-bonds | hydrophobic | π-cation | π–π stacking | salt bridges | XP GScore(kcal/mol) | ΔGbind(kcal/mol) |
|---|---|---|---|---|---|---|---|---|
| CYP2D6 | RTZ | LEU110, PHE120, ALA209, LEU213, GLN244, PHE247, ILE297, ALA300, VAL308, PHE483, LEU484 | GLU216, ASP301 | –7.07 | –72.57 | |||
| M30 | LEU213, GLU216, THR309, VAL370, VAL374 | –6.20 | –73.78 | |||||
| M35 | SER304 | PHE120, ASP301, ALA305, THR309, VAL370, VAL374 | –6.02 | –65.40 | ||||
| M37 | PHE120, LEU213, VAL374, PHE483 | –7.27 | –85.15 | |||||
| M38 | PHE120, LEU213, VAL374, PHE483 | –7.48 | –83.12 | |||||
| M39 | GLN244 | PHE120, GLN244, ALA300 | ASP301 | –7.12 | –67.86 | |||
| M44 | SER304 | PHE120, LEU213, GLU216, VAL374, PHE483 | –6.69 | –64.36 | ||||
| CYP3A4 | RIT | SER119, ARG372, LEU483 | PHE57, ARG106, PHE108, ILE120, LEU210, PHE213, PHE215, THR224, PHE241, ILE301, PHE304, ILE369, LEU373 | PHE213 | –10.03 | –62.42 | ||
| M33 | SER119, THR309 | ILE120, PHE241, ILE301 | –6.94 | –60.45 | ||||
| M38 | THR309 | PHE108 | ARG105 | –6.49 | –70.96 | |||
| M39 | ILE301, PHE304 | –6.93 | –65.95 | |||||
| M40 | ILE369, MET371, ARG372, LEU483 | ILE369, LEU482 | –8.81 | –66.66 | ||||
| M41 | ILE369, MET371, ARG372, GLY481, LEU483 | PHE304, ILE369, LEU482 | –8.34 | –73.48 | ||||
| M42 | THR309, ILE369, LEU483 | ILE369, LEU482 | –10.15 | –65.89 |
Thioridazine (RTZ) and ritonavir (RIT) were taken as control inhibitors. The interactions analysis was performed using online web tool protein-ligand interaction profiler (PLIP). M30: piperidine, 1-(5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)-; M33: N-formylannonaine; M35: dasycarpidan-1-methanol, acetate (ester); M37: berberine; M38: jatrorrhizine; M39: luteanine; M40: (±)-corydine; M41: (+)-magnoflorine iodide; M42:7-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-ium; M44: rotundine.